Skip to main content
Article thumbnail
Location of Repository

Preliminary Characterisation of FAM129C, a Novel Protein Identified from Proteomic Screening of CLL Samples

By Renata Janina Walewska


The principal aim of this thesis was to begin to determine the possible functions of a novel and B-cell specific protein, FAM129C, identified from proteomic screening of purified CLL plasma membrane fractions. Bioinformatic analysis showed that FAM129C contained a pleckstrin homology domain that probably causes the protein to be associated with the plasma membrane but lacked any other obvious domains. Using quantitative RT-PCR, I showed that FAM129C was expressed from early stages of B-cell differentiation. It was expressed at high levels in chronic lymphocytic leukaemia (CLL) and in the activated subtype of diffuse large B-cell lymphoma, where it may be a useful diagnostic marker. FAM129C was also expressed at high levels in normal B-cell populations including both naïve pre-germinal centre and memory cell populations but interestingly was rapidly down-regulated following stimulation to proliferation. Similar down-regulation was also observed in CLL cells stimulated to proliferation in vitro. Similar down-regulation was also observed in CLL cells stimulated to proliferate in vitro. Subcellular fraction studies of FAM129C showed wide expression in many different cell fractions, but mainly in the cytoplasm. The pattern of FAM129C expression was similar to that of CXCR4 and, therefore I have speculated that there is a potential association between these two proteins in B cell development and in B cell maturation during germinal centre reaction

Publisher: University of Leicester
Year: 2011
OAI identifier:

Suggested articles


  1. (2008). A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. doi
  2. (2002). Angiotropic lymphoma occurring in a lacrimal sac oncocytoma.
  3. Annual Meeting Abstracts); doi
  4. (1646). Appendix: Authour‘s publications Other publications: 14. Walewska
  5. (2000). Audit of Transfusion in Paediatric Patients‘: poster presentation at the XVIII annual meeting of British Blood Transfusion Society,
  6. (2007). BCL2 expression in chronic lymphocytic leukemia (CLL): lack of association with the BCL2 -938A>C promoter single nucleotide polymorphism (SNP). doi
  7. (2009). Caspase cleavage of Itch in chronic lymphocytic leukaemia cells. doi
  8. (1995). CD40 Appendix: Leicester CLL Database: The Results achi-square; bone-way ANOVA; cKruskal Wallis; dMantel-Cox (log rank) ; in red are marked statistically signif icant differences, green: marginal signif icance;
  9. (2000). Cold haemagglutinin disease: clinical significance of serum haemolysins. doi
  10. (2008). Concurrent upregulation of BCL-XL and BCL2A1 induces~1000-fold resistance to ABT-737 in chronic lymphocytic leukaemia. Blood,
  11. (2008). Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. doi
  12. (2007). Erythema annulare centrifugum associated with chronic lymphocytic leukaemia. doi
  13. (1995). Evaluation of comparative protein modeling by MODELLER. doi
  14. (2009). FAM129C a novel B cell protein is downregulated during CD40cell activation but not BCR stimulation. Poster accepted for presentation at the BSH 49th Annual Scientific Meeting,
  15. (2000). Fatal cold anti-i autoimmune haemolytic anaemia complicating hairy cell leukaemia. doi
  16. (2007). Identifying Progressive CLL-a Study of Clinical and Genetic Features Associated within an Ethnically Diverse Population in Leicestershire.
  17. (2005). Increasing the dose intensity of alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia (CLL): The CAM1515 study. Blood, 106, 830A-830A 25. Dunnion
  18. (2006). Inhibition of bortezomib-induced apoptosis by red blood cell uptake. doi
  19. (2007). Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69. doi
  20. (2004). Mcl-1 and Bcl2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. doi
  21. (2007). members of the CEBP transcription factor family are targeted by recurrent IGH-translocations in B-cell precursor acute lymphoblastic leukemia doi
  22. (2002). Molecular Cloning, 3rd Ed.:
  23. (2009). Protein profiling of plasma membranes defines aberrant signalling pathways in mantle cell lymphoma. Mol Cell Proteomics. doi
  24. (2010). Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica. doi
  25. (2002). Ten year evaluation of selective antenatal screening for Hb disorders in intermediate incidence area. Trends in service provision and effectiveness.
  26. (1999). The role of c-FLIP in modulation of CD95-induced apoptosis. doi
  27. (2008). Time to first treatment; Comparison of overall survival between Mayo cohort
  28. (2007). TRAIL signals to apoptosis in CLL cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2 doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.